Company Announcement no. 7/2011


To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, June 6, 2011



LifeCycle Pharma announces receipt of DKK 3.9m Grant from The Danish National
Advanced Technology Foundation to support development of an oral chemotherapy
agent



LifeCycle Pharma A/S (OMX:LCP) today announced that it received a grant of DKK
3.899.289 from The Danish National Advanced Technology Foundation to support
collaborative work with Herlev Hospital, Copenhagen, Denmark on the development
of an oral chemotherapeutic agent to potentially replace an existing agent that
requires intravenous administration.


New research from LifeCycle Pharma A/S indicates that certain types of
intravenous chemotherapy can be modified, using LifeCycle Pharma A/S
technologies, to pill-based therapy which the patient can take in an
out-patient setting. Intravenous therapy can be stressful for patients, may be
accompanied by side-effects and is expensive for the healthcare system.


Recent research has shown that small daily doses of certain types of
chemotherapy have better effect than a larger dose given with longer intervals.
Additionally, small frequent doses may minimize side effects. However, it is
not practicable for either patients or the hospital system to treat patients
with daily chemotherapy infusions. By developing a pill, which the patient can
take at home, it will be feasible to offer patients a less resource demanding
and potentially a less toxic and more effective treatment.


Professor Dorte Nielsen, Chief Physician of Herlev Hospital's Oncology
Department, says, "Herlev Hospital looks forward to utilizing our extensive
expertise in chemotherapy to improve cancer treatment for the benefit of our
patients." LifeCycle Pharma's Senior Vice President for Pharmaceutical
Development & CMC, Peter G. Nielsen added, "We are very pleased with the grant
from the Advanced Technology Foundation which will enable us to utilize our
technologies and extensive experience in working with hard-to-dose drugs in
oral form to develop novel chemotherapy products for the benefit of patients
and the society".



For more information, please contact:



LifeCycle Pharma A/S Johnny Stilou
John Weinberg, M.D. CFO
SVP, Commercial Operations & Investor Relations Phone: + 45 2055 3817
Phone: +1 732 321 3208 Email: [email protected]
Email: [email protected]



About LifeCycle Pharma A/S (LCP)

LCP is a specialty pharmaceutical company. Clinical development is the core of
LCP's efforts to develop a product portfolio which includes the Company's lead
product candidate, LCP‐Tacro™, for immunosuppression, specifically organ
transplantation, and products to combat certain cardiovascular diseases. LCP
adapts new technologies on a fast commercial timetable. LCP's unique, patented
delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at
low‐scale up costs ‐ not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a lipid lowering product,
Fenoglide®, currently on the U.S. market and a diversified near and medium term
pipeline with three clinical stage product candidates and a number of projects
in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under
the trading symbol OMX: LCP. For further information, please visit
www.lcpharma.com.


Forward-looking statement safe-harbor

All statements other than statements of historical facts included in this
announcement are forward-looking statements that are subject to certain risks,
trends and uncertainties that could cause actual results and achievements to
differ materially from those expressed in such statements. These risks, trends
and uncertainties are in some instances beyond our control. Words such as
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and
other similar expressions identify forward-looking statements, although not all
forward-looking statements contain these identifying words. In particular, any
statements regarding clinical trial results and potential regulatory approval
for LCP-Tacro are considered forward-looking statements. These forward-looking
statements involve substantial risks and uncertainties and are based on our
assessment and interpretation of the currently available data and information,
current expectations, assumptions, estimates and projections about our business
and the biopharmaceutical and specialty pharmaceutical industries in which we
operate. Important factors that may affect our ability to achieve the matters
addressed in these forward-looking statements include, but are not limited to
whether the results of our Phase 3 clinical trials of LCP-Tacro meet the
predetermined endpoints for such trial; our ability to complete the development
of, obtain regulatory approval for, and commercialize, LCP-Tacro; our ability
to hire and retain personnel in a competitive industry; our reliance on third
parties to manufacture LCP-Tacro and to conduct clinical trials for LCP-Tacro;
competition from existing therapies and therapies that are currently under
development, including Prograf® (tacrolimus), Advagraf® (tacrolimus), and
belatacept; whether we are able to obtain additional financing, if needed;
risks of maintaining protection for our intellectual property; risks of an
adverse determination in intellectual property litigation; and risks associated
with stringent government regulation of the biopharmaceutical industry. We may
not actually achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance on our
forward-looking statements, which speak only as of the date hereof. Actual
results or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that we make. We do
not have a policy of updating or revising forward-looking statements and,
except as required by law, assume no obligation to update any forward-looking
statements.

060611 LCP Development of an Oral Chemotherapy Agent.pdf